ReviewTransfusion2015
Pathogenesis and mechanisms of antibody-mediated hemolysis.
Review in Transfusion, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations.Transfusion · 2022Pooled it
- When is ABO-incompatible plasma safe to transfuse? Defining an empirical estimation of anti-A/anti-B in ABO incompatible plasma-containing blood products.Blood transfusion = Trasfusione del sanguePooled it
- Trial
- Standardization of the Monocyte Monolayer Assay: Lessons Learned From Laboratory Optimization and Literature Review.Journal of clinical laboratory analysis · 2026Article
- Effects of prosthetic heart valve-associated subclinical intravascular hemolysis on endothelium and cardiovascular system: a retrospective cohort study.Heart and vessels · 2026Article
- Article
- Hemolysis-induced hepatic ferroptosis following xenotransfusion of genetically modified pig red blood cells.Scientific reports · 2025Article
- Passenger lymphocyte syndrome - Epidemiology, pathogenesis, diagnosis, treatment and future directions: A review.Biomolecules & biomedicine · 2025Review
- A Rare Case of Warm Autoimmune Hemolytic Anemia With Intravascular Hemolysis: A Case Report.Cureus · 2025Article
- Evaluation of two methods for detecting anti-A and anti-B hemolysins in blood donors: a prospective study in Abidjan.The Pan African medical journal · 2025Article
- Establishment and Clinical Application of Rh Blood Group Bank in the East China Region.International journal of general medicine · 2025Article
- Alloantibody Identification: The Importance of Temperature, Strength Reaction and Enzymes-A Practical Approach.Hematology reports · 2024Article
- Red Blood Cell Membrane-Coated Nanoparticles Enable Incompatible Blood Transfusions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Hemolytic anemia associated with intravenous immunoglobulin in Kawasaki disease.BMC pediatrics · 2024Article
- Characteristics of ABO Antibodies in Group O Malaysian Blood Donors.The Malaysian journal of medical sciences : MJMS · 2023Article
- Clinical Reasoning: A 23-Year-Old Man With Progressive Asymmetric Weakness and Numbness.Neurology · 2023Article
- Pathogenesis of Anemia in Canine Babesiosis: Possible Contribution of Pro-Inflammatory Cytokines and Chemokines-A Review.Pathogens (Basel, Switzerland) · 2023Review
- Anemia in the pediatric patient.Blood · 2022Article
- Methods to Evaluate the Potential Clinical Significance of Antibodies to Red Blood Cells.Current protocols · 2022Article
- A New Trial to Measure ABO Antibodies Using Complement-Dependent Cytotoxicity.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundThe clinical consequences of antibodies to red blood cells (RBCs) have been studied for a century. Most clinically relevant antibodies can be detected by sensitive in vitro assays. Several mechanisms of antibody-mediated hemolysis are well understood. Such hemolysis after transfusion is reliably avoided in a donor-recipient pair, if one individual is negative for the cognate antigen to which the other has the antibody. STUDY DESIGN AND
resultsMechanisms of antibody-mediated hemolysis were reviewed based on a presentation at the Strategies to Address Hemolytic Complications of Immune Globulin Infusions Workshop addressing intravenous immunoglobulin (IVIG) and ABO antibodies. The presented topics included the rates of intravascular and extravascular hemolysis; immunoglobulin (Ig)M and IgG isoagglutinins; auto- and alloantibodies; antibody specificity; A, B, A,B, and A1 antigens; A1 versus A2 phenotypes; monocytes-macrophages, other immune cells, and complement; monocyte monolayer assay; antibody-dependent cell-mediated cytotoxicity; and transfusion reactions due to ABO and other antibodies.
conclusionSeveral clinically relevant questions remained unresolved, and diagnostic tools were lacking to routinely and reliably predict the clinical consequences of RBC antibodies. Most hemolytic transfusion reactions associated with IVIG were due to ABO antibodies. Reducing the titers of such antibodies in IVIG may lower the frequency of this kind of adverse event. The only way to stop these events is to have no anti-A or anti-B in the IVIG products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.